Acquired mechanisms of resistance to osimertinib-the next challenge

Citació

  • Ríos-Hoyo A, Moliner L, Arriola E. Acquired mechanisms of resistance to osimertinib-the next challenge. Cancers (Basel). 2022 Apr 12; 14(8): 1931. DOI: 10.3390/cancers14081931

Enllaç permanent

Descripció

  • Resum

    EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventually acquire mechanisms of resistance. In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them.
  • Mostra el registre complet